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Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disorder of the 
central nervous system caused by JC virus that occurs in those with impaired immune 
systems. Existing treatment options are ineffective or unproven. This article reviews recent 
research into novel therapies: 1) immune checkpoint blocking antibodies (nivolumab and 
pembrolizumab); 2) allogenic BK virus-specific T cell treatment and 3) filgrastim. Results for 
these therapies in small clinical trials are promising, but further research is required to assess 
efficacy fully.  
 
Case Study  
A 67-year-old man presented with left-sided weakness and reduced left hand dexterity four 
months after autologous stem-cell transplant for multiple myeloma. He had no other past 
medical history. Computerised tomography scan of the head showed multiple areas of low 
attenuation and magnetic resonance imaging demonstrated numerous hyper-intense T2 
lesions within the subcortical white matter of both cerebral hemispheres. Over 6 months his 
clinical symptoms continued to progress such that he developed emotional lability, motion 
sickness, cognitive dysfunction and was unable to walk 2 metres unaided. An extensive set of 
investigations were performed to determine the cause. John Cunningham virus (JC virus) was 
found to be positive along with compatible clinical and radiological findings which met the 
diagnostic criteria for Progressive multifocal leukencephalopathy (PML) (Berger et al 2013). 
In this case there was no scope to improve immune functioning and he was commenced on 
mirtazapine as a potential anti-viral therapy. Despite this intervention he continued to 
deteriorate and died shortly afterwards (Bennett et al., 2020).  
Introduction  
PML is a rare demyelinating disorder of the central nervous system caused by JC virus, a 
neurotropic polyomavirus. JC virus is present in around 50% of the population, causing an 
asymptomatic latent infection in the renal tract and/or bone marrow (Sabath & Major, 2002). 
Failure of immune control allows penetration of the virus into the central nervous system, 
resulting in widespread oligodendrocyte lysis (Major et al., 2018), often with devastating 
consequences. The clinical presentation varies depending on the location and extent of 
demyelination, but symptoms often include muscle weakness, sensory deficit, hemianopia, 
cognitive dysfunction and coordination difficulties (Pavlovic et al., 2015). 
  
PML usually only affects those who are immunosuppressed (Clifford, 2015) with three 
associations accounting for 90% of cases: 1) human immunodeficiency virus (HIV); 2) 
immunosuppressing haematological malignancies, and 3) multiple sclerosis patients treated 
with natalizumab (Pavlovic et al., 2015). Less commonly, PML is associated with organ 
transplantation, solid malignancies, sarcoidosis, autoimmune disorders and other 
immunosuppressant medications (e.g. prednisolone, dimethyl fumarate and rituximab) 
(Maas et al., 2016; Pavlovic et al., 2015).  
  
The diagnostic criteria for PML are either characteristic findings on brain biopsy or a 
combination of the appropriate clinical symptoms, radiological features and JC virus in the 
cerebrospinal fluid (CSF) (Berger et al., 2013). Prognosis in PML is poor unless 
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immunosuppression can be reversed (Pavlovic et al., 2015). In a Swiss HIV cohort, patients 
infected with PML had a 1-year mortality rate of 30%, even with highly active antiretroviral 
therapy (HAART), though this is much improved compared to the rate of 83% in the pre- 
HAART era (Khanna et al., 2009). In those with multiple sclerosis treated with natalizumab 
77% are alive at three years and in those with active immunosuppressing haematological 
malignancies just 10% are alive beyond two months (Pavlovic et al., 2015).  
 
The restoration of central nervous system (CNS) immunocompetence in PML patients carries 
the risk of immune reconstitution inflammatory syndrome (PML-IRIS) (McCarthy & Nath, 
2010). This is defined as the paradoxical sudden worsening of PML signs and symptoms in the 
setting of immune reconstitution, often with contrast enhancement in the PML lesion on MRI. 
The pathophysiological process in IRIS is thought to be high levels of inflammation causing 
damage to previously intact brain tissue; this can be fatal if significant vasogenic oedema 
occurs. Treatment of PML-IRIS is with high dose corticosteroids to reduce CNS inflammation.  
 
Existing treatments 
Current treatment options for PML focus on restoring immune function through reversing 
exogenous immunosuppression. For example, patients with HIV are started on HAART and 
patients on natalizumab have their treatment stopped, often using plasma exchange to more 
rapidly eliminate the drug from the circulation.  However, in some circumstances, 
immunosuppression cannot be reversed, such as in patients with heart-lung transplants or 
patients with conditions causing intrinsic immunosuppression e.g.  sarcoidosis or primary 
immunodeficiency. In these situations, the only remaining therapeutic possibility is to attack 
the virus. Pavlovic et al conducted a review of these potential options, dividing them into anti-
viral agents, immune response modulators, and immunisation strategies (Pavlovic et al., 
2015). As shown in Table 1, small-scale clinical trials have taken place for the following drugs: 
cytarabine, topotecan, cidofovir, mefloquine, interferon-alpha 2b and zidovudine; all have 
demonstrated negative or inconclusive results. Research for other drug options are limited to 
case studies and retrospective studies with no strong consensus. The identification of 
successful treatments is challenged by inadequate animal models, small patient numbers and 
rapid disease progression.  
 
Treatment with interleukin-7 (IL-7) aims to boost depleted T-cell response. It is a cytokine 
which stimulates proliferation of cells in the lymphoid lineage and supports their maturation, 
survival and homeostasis (Pavlovic et al., 2015). Individual case studies have reported 
promising results on the use of IL-7 in treating those with PML and idiopathic 
lymphocytopenia (Alstadhaug et al., 2014; Harel et al., 2016; Miskin et al., 2016).  
 
Table 1: Current medications used to treat PML (Pavlovic et al., 2015) 
 Drug name  Presumed mechanism Efficacy in clinical trials 
Anti-viral 
agents 
Mefloquine Inhibits viral replication Negative/inconclusive 
Mirtazepine Blocks serotonin receptors None  
Cidofovir Inhibits infection Negative 
Ganciclovir Inhibits viral polymerases None 
Topotecan Inhibits replication Inconclusive/poorly tolerated 
Cytarabine Decrease replication Negative 




IL-2 Increases T cell function  None  
IL-7  Increases lymphoid proliferation  None 
Maraviroc  Decreases inflammation  None  
Corticosteroids  Decreases inflammation  None  
Immunisation 
strategies  
Intravenous immunoglobulin (IVIg) Uncertain None 
Anti-JCV Ab Neutralises virus None  
Anti-JC virus vaccine Neutralises virus None  
  
Novel PML treatments 
Recent research has begun to test novel immune boosting agents in the treatment of PML. 
These comprise three main groups of therapies, all of which show promise: 1) immune 
checkpoint blocking antibodies (nivolumab and pembrolizumab); 2) allogenic BK virus-specific 
T-cell treatment and 3) filgrastim. 
 
Immune checkpoint blocking antibodies: nivolumab and pembrolizumab  
The immune system has a complex set of checks and balances to avoid damaging over-
stimulation, known as immune checkpoints. One aspect of this process involves programmed 
cell death-1 (PD-1) a negative immune regulator expressed on activated T cells. Nivolumab 
and pembrolizumab are anti-cancer drugs that block this inhibitory pathway, reinvigorating 
T-cell activity, and thereby boosting the immune response against cancer (Wykes & Lewin, 
2018). Both drugs have similar pharmacological features, differing on the precise PD-1 
epitope recognised, and are licensed in the UK for the treatment of melanoma, Hodgkin’s 
lymphoma, and non-small cell lung cancer (Koralnik, 2019).  
 
An indication of the potential benefit of immune checkpoint inhibitors against JC virus came 
from the finding that PD-1 expression is elevated on the CD4+ and CD8+ T lymphocytes of 
patients with PML and is especially elevated on JC virus-specific CD8+ T cells (Tan et al., 2012). 
Initial clinical studies have been promising, with Cortese et al. presenting a case series of eight 
patients treated with pembrolizumab for PML (Cortese et al., 2019). These patients had a 
mixture of underlying conditions including HIV, haematological malignancies (chronic 
lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma), and idiopathic 
lymphopenia. All eight patients showed down-regulation of lymphocytes in the peripheral 
blood and CSF prior to pembrolizumab treatment. After pembrolizumab treatment five 
patients showed clinical improvement or stabilisation, with concomitant reduction in CSF JC 
viral load and increased in-vitro CD4+ and CD8+ anti JC virus activity. In three of the eight 
patients there was no clinical improvement and no change in viral load. In retrospect one of 
the five patients showing clinical improvement was noted to have had some clinical, 
radiologic and virologic stabilisation of PML before treatment. Two of the five patients 
showing clinical improvement had HIV and were concurrently started on antiretroviral 
therapy which will have contributed to immune system restoration (Koralnik, 2019). None of 
the patients had complete resolution of PML brain lesions.  
 
Promising results with pembrolizumab or nivolumab have also been demonstrated in 
individual case studies, with outcomes ranging from partial to full recovery (Audemard-Verger 
et al., 2019; Hoang et al., 2019; Uzunov et al., 2019; Walter et al., 2019). Perhaps 
unsurprisingly, patients treated early seemed to do better than those treated with late-stage 
disease. A case series of nivolumab usage in three patients with kidney transplants and PML 
showed poor outcomes, with all three dying shortly after diagnosis (Medrano et al., 2019). 
Interestingly, these three patients and the three patients with no clinical improvement 
described by Cortese et al (2019) all had significant lymphopenia, suggesting the use of 
immune checkpoint blocking antibodies may be limited in this subset of patients. These 
studies are summarised in Table 2. Additionally, there are no reports of the successful use of 
immune checkpoint inhibitors in organ transplant patients (Focosi et al., 2019).  
 
Table 2:  Outcomes of patients with PML treated with immune checkpoint inhibitors. 
Treatment  Age/sex  Underlying 
condition(s)  
Time between onset 
of symptoms and 
treatment initiation 
CSF viral load at 
treatment onset  
(copies per ml) 
PML-
IRIS  
Outcome  Reference  
Pembrolizumab 67/M Chronic 
lymphocytic 
leukaemia  
15 months  232 No (=) Symptoms stabilised prior to 
treatment 
(Cortese et al., 2019) 1  
Pembrolizumab 78/M Chronic 
lymphocytic 
leukaemia 
7 months  6044 No  (+) Confusion, language and 
ataxia improved slightly. 
(Cortese et al., 2019) 2  
Pembrolizumab 48/F HIV/AIDS 6 months 63 No  (+) Improvement in language 
and cognition, independent in 
activities of daily living. 
(Cortese et al., 2019) 3  
Pembrolizumab 69/F Non-Hodgkin 
lymphoma 
12 months  26,494 No  (-) Clinical deterioration.  (Cortese et al., 2019) 4 
Pembrolizumab 31/M Idiopathic 
lymphopenia 
2 months 5,248 No  (+) Improvement in confusion 
and increased independence 
with activities of daily living.  
(Cortese et al., 2019) 5 




3 months 28,350 No  (-). Clinical deterioration and 
became wheelchair bound. 
(Cortese et al., 2019) 6 
Pembrolizumab 70/M Hodgkin’s 
lymphoma 
2 261 No  (+) Modest improvements in gait 
and speech. 
(Cortese et al., 2019) 7 
Pembrolizumab 58/M HIV/AIDS 12 286 No (+) Subjective clinical 
improvement. 
(Cortese et al., 2019) 8 
Pembrolizumab 42/M Idiopathic primary 
immunodeficiency  
5 months  38 No  (-) Clinical deterioration. (Kupper et al., 2019) 




4 weeks 2,561,955 No (-) Died 4 weeks after treatment 
initiation.  





and diffuse B cell 
lymphoma. 
10 weeks 119,000 Yes (+) Speech recovery but ongoing 
psychomotor slowing, aphasia 
and disorientation  
(Rauer et al., 2019) 
Nivolumab 53/M Silicosis  12 weeks Not detected No  (++) Stabilised aphasia and 
regression of motor deficit.  
(Audemard-Verger et 
al., 2019) 
Nivolumab 65/F Hodgkin’s 
Lymphoma 
0 days Not detected Yes (++) Clinical function improved. (Hoang et al., 2019) 
Nivolumab 81 Kidney transplant  <6 weeks  3,162 No  (-) Death 6 weeks after 
diagnosis.  
(Medrano et al., 2019) 1 
Nivolumab 77 Kidney transplant <6 weeks  794 No  (-) Death 6 weeks after 
diagnosis. 
(Medrano et al., 2019) 2 
Nivolumab 67 Kidney transplant  <6 weeks  794 No  (-) Death 4 weeks after 
diagnosis. 
(Medrano et al., 2019) 3 




4 weeks  47,377  No (++). Complete recovery from 
motor deficit. Visual symptoms 
stabilised. 
(Uzunov et al., 2019) 
Nivolumab 60/F Idiopathic primary 
immunodeficiency  
8 weeks 200,000 Yes (++) Improved focal deficits and 
alertness. 
(Walter et al., 2019) 
Key: (−) unfavorable outcome; (+) mild improvement; (++) marked improvement and (=) no 
change. IRIS = immune reconstitution inflammatory syndrome. F = female and M = male.  
 
The development of immune reconstitution inflammatory syndrome (IRIS) in PML patients 
treated with immune checkpoint inhibitors was variable. In the cases showing clinical 
improvement, some did show IRIS (Hoang et al., 2019; Rauer et al., 2019) but this was not 
universal (Audemard-Verger et al., 2019; Cortese et al., 2019; Walter et al., 2019). Thus, IRIS 
does not appear to be a prerequisite for clinical improvement, though differentiating 
between PML-IRIS and PML alone can be challenging. It should be noted that none of the 
patients with poor outcomes developed IRIS, indicating that IRIS may be an indicator of a 
positive outcome. Other side-effects of immune checkpoint inhibitors in PML cohorts include 
rashes (Cortese et al., 2019), diarrhoea (Rauer et al., 2019) and myositis (Uzunov et al., 2019). 
In cancer cohorts immune checkpoint inhibitors are associated with serious side effects 
involving all organ systems (Heinzerling & Goldinger, 2017) including myasthenia gravis and 
cardiotoxicity (Hottinger, 2016; Suzuki et al., 2017). One case report details PML developing 
after treatment with nivolumab in a patient with refractory stage IV Hodgkin lymphoma 
(Martinot et al., 2018); though it cannot be determined whether PML was caused by 
nivolumab or the underlying immunocompromised state.  
 
There does not appear to be a discernible difference between nivolumab and pembrolizumab 
and there are no reports on other immune checkpoint inhibitors such as ipilimumab, 
atezolizumab, avelumab or durvalumab. All these treatments are expensive and use in PML 
patients is currently unlicensed.   
  
Allogeneic BK virus-specific T cells 
BK is a polyoma virus closely related to JC virus, causing renal tract infections in 
immunocompromised patients after stem-cell or solid organ transplant.  A novel treatment 
for BK virus infections involves screening donated blood for BK-specific T-cells, clonally 
expanding these cells, and transfusing these into BK-infected immunocompromised patients, 
with promising results (Tzannou et al., 2017). It was therefore postulated that T-cells 
developed against BK virus may also be effective against JC virus, due to the similarities 
between these related pathogens. This theory was tested in three patients with different 
underlying conditions: acute myeloid leukaemia treated with cord–blood transplant, 
myeloproliferative neoplasm treated with ruxolitinib, and HIV treated with HAART 
(Muftuoglu et al., 2018). Each patient received HLA-matched BK virus-specific T-cells. In two 
patients (myeloproliferative neoplasm treated with ruxolitinib and HIV treated with high 
active retroviral therapy) there was significant clinical improvement. JC virus in the CSF 
disappeared and lesions on MRI decreased. Both patients developed IRIS. However, these 
results are confounded by the respective discontinuation of ruxolitinib and the 
commencement of anti-retroviral therapy. The third patient stabilised but did not improve, 
with concomitant reduction – but not clearance – of CSF JC virus.  She died 8 months after 
starting treatment. The authors postulate that the lack of clinical improvement in this patient 
may have been due to late initiation of anti-PML treatment. No side effects from allogeneic 
T-cell therapy were reported in any patient.  The heterogeneity in underlying conditions in 
this small case series and the use of multiple treatments makes assessing efficacy challenging. 
The potential use of patient-specific products and/or third-party products may expand the 
feasibility of this therapy (Fatic et al., 2020).  
  
Filgrastim  
Filgrastim (also known as granulocyte colony-stimulating factor) is often used to boost the 
immune system after chemotherapy. It promotes production of granulocytes, lymphocytes, 
antigen presenting cells and improves adhesion of T-cells to the blood vessel wall. These 
features promote immune system function, potentially enabling an anti-PML effect.  
  
Stefoski et al published a retrospective cohort study of 17 patients treated with filgrastim for 
natalizumab induced PML (Stefoski et al., 2019). Natalizumab was stopped in all patients after 
PML diagnosis. All patients were treated with daily filgrastim until lymphocyte counts 
doubled. In addition, 8 patients underwent plasma exchange, 14 received mefloquine, 15 
received mirtazapine, and 9 were treated with maraviroc. 15 patients developed IRIS which 
was treated with intravenous methylprednisolone followed by tapering doses of 
corticosteroids. Filgrastim was well-tolerated, with the only side effect reported being bone 
pain not necessitating cessation of treatment. Outcomes were very good, with all 17 patients 
surviving 2-years after PML onset; survival after natalizumab induced PML has been reported 
in other cohorts as 76% (Dong-Si et al., 2015). Functional outcomes were mixed, with 7 
patients improving to baseline at PML diagnosis, 3 improving but not to baseline, and 7 having 
poor outcomes (requiring full care). Patients who developed immune activation after 
filgrastim and/or IRIS had better clinical outcomes; the authors note that careful timing of 
steroid treatment for PML-IRIS is important. Plasma exchange had no effect on outcome. The 
retrospective nature of the study and the use of multiple drugs means that cause and effect 
are difficult to establish. The benefit of this study was that the population was a homogenous 
MS population allowing more specific conclusions about PML in this population to be drawn. 
 
Conclusion 
PML is a devastating disease, especially when immunosuppression cannot be reversed. 
Previous treatments have not been shown to be efficacious in clinical trials. The growing 
number of patients with iatrogenic immunosuppression is likely to result in a rising PML 
incidence, highlighting the importance of developing effective anti-PML therapies. Novel 
treatments for PML focus on boosting the anti-JC virus immune response via immune 
checkpoint inhibitors (pembrolizumab and nivolumab), BK-specific T-cell therapy, and 
filgrastim, all of which have shown benefit in cohort studies. Limitations of these studies 
include small sample sizes, heterogeneous patient cohorts, and multiple confounding factors. 
As usage of these expensive therapies increase it may be possible to identify patient factors 
that predict good response and to develop combinatory treatment modalities. Future studies 
should test these treatment methods in more specified patient groups, with standardized 
outcome measures. A multi-centre randomised controlled trial would be the best way of 
showing efficacy, though the rarity of PML may make this approach challenging. Despite the 
initial promise of these novel treatments it is important to set realistic patient expectations 
given that many patients remain extremely disabled even after successful PML treatment.   
 
KEY POINTS 
 PML is a devastating disease with poor prognosis, particularly where 
immunosuppression cannot be reversed.  
 Existing treatments are ineffective or unproven. 
 Novel treatments for PML boost the anti-JC virus immune response via immune 
checkpoint inhibitors (pembrolizumab and nivolumab), BK-specific T-cell therapy, and 
filgrastim. 
 These treatments have shown benefit in cohort studies, but conclusions are limited 
by small sample sizes, heterogeneous patient cohorts, and multiple confounding 
factors. 
 Multi-centre randomised controlled trials will help establish why treatment appears 
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Table 1: Current medications used to treat PML (Pavlovic et al., 2015) 
 Drug name  Presumed mechanism Efficacy in clinical trials 
Anti-viral 
agents 
Mefloquine Inhibits viral replication Negative/inconclusive 
Mirtazepine Blocks serotonin receptors None  
Cidofovir Inhibits infection Negative 
Ganciclovir Inhibits viral polymerases None 
Topotecan Inhibits replication Inconclusive/poorly tolerated 




Interferon A Increases cell-mediated immunity Negative 
IL-2 Increases T cell function  None  
IL-7  Increases lymphoid proliferation  None 
Maraviroc  Decreases inflammation  None  
Corticosteroids  Decreases inflammation  None  
Immunisation 
strategies  
Intravenous immunoglobulin (IVIg) Uncertain None 
Anti-JCV Ab Neutralises virus None  
Anti-JC virus vaccine Neutralises virus None  
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Table 2:  Outcomes of patients with PML treated with immune checkpoint inhibitors. 
Treatment  Age/sex  Underlying 
condition(s)  
Time between onset 
of symptoms and 
treatment initiation 
CSF viral load at 
treatment onset  
(copies per ml) 
PML-
IRIS  
Outcome  Reference  
Pembrolizumab 67/M Chronic 
lymphocytic 
leukaemia  
15 months  232 No (=) Symptoms stabilised prior to 
treatment 
(Cortese et al., 2019) 1  
Pembrolizumab 78/M Chronic 
lymphocytic 
leukaemia 
7 months  6044 No  (+) Confusion, language and 
ataxia improved slightly. 
(Cortese et al., 2019) 2  
Pembrolizumab 48/F HIV/AIDS 6 months 63 No  (+) Improvement in language 
and cognition, independent in 
activities of daily living. 
(Cortese et al., 2019) 3  
Pembrolizumab 69/F Non-Hodgkin 
lymphoma 
12 months  26,494 No  (-) Clinical deterioration.  (Cortese et al., 2019) 4 
Pembrolizumab 31/M Idiopathic 
lymphopenia 
2 months 5,248 No  (+) Improvement in confusion 
and increased independence 
with activities of daily living.  
(Cortese et al., 2019) 5 




3 months 28,350 No  (-). Clinical deterioration and 
became wheelchair bound. 
(Cortese et al., 2019) 6 
Pembrolizumab 70/M Hodgkin’s 
lymphoma 
2 261 No  (+) Modest improvements in gait 
and speech. 
(Cortese et al., 2019) 7 
Pembrolizumab 58/M HIV/AIDS 12 286 No (+) Subjective clinical 
improvement. 
(Cortese et al., 2019) 8 
Pembrolizumab 42/M Idiopathic primary 
immunodeficiency  
5 months  38 No  (-) Clinical deterioration. (Kupper et al., 2019) 




4 weeks 2,561,955 No (-) Died 4 weeks after treatment 
initiation.  





and diffuse B cell 
lymphoma. 
10 weeks 119,000 Yes (+) Speech recovery but ongoing 
psychomotor slowing, aphasia 
and disorientation  
(Rauer et al., 2019) 
Nivolumab 53/M Silicosis  12 weeks Not detected No  (++) Stabilised aphasia and 
regression of motor deficit.  
(Audemard-Verger et 
al., 2019) 
Nivolumab 65/F Hodgkin’s 
Lymphoma 
0 days Not detected Yes (++) Clinical function improved. (Hoang et al., 2019) 
Nivolumab 81 Kidney transplant  <6 weeks  3,162 No  (-) Death 6 weeks after 
diagnosis.  
(Medrano et al., 2019) 1 
Nivolumab 77 Kidney transplant <6 weeks  794 No  (-) Death 6 weeks after 
diagnosis. 
(Medrano et al., 2019) 2 
Nivolumab 67 Kidney transplant  <6 weeks  794 No  (-) Death 4 weeks after 
diagnosis. 
(Medrano et al., 2019) 3 




4 weeks  47,377  No (++). Complete recovery from 
motor deficit. Visual symptoms 
stabilised. 
(Uzunov et al., 2019) 
Nivolumab 60/F Idiopathic primary 
immunodeficiency  
8 weeks 200,000 Yes (++) Improved focal deficits and 
alertness. 
(Walter et al., 2019) 
Key: (−) unfavorable outcome; (+) mild improvement; (++) marked improvement and (=) no 
change. IRIS = immune reconstitution inflammatory syndrome. F = female and M = male.  
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